In summary, we have successfully developed an EGFR/HER3 targeting immunoPET companion diagnostic to MEHD7945A (duligotuzumab) and evaluated its properties in the preclinical setting. This probe has high potential to non-invasively delineate and stage EGFR and HER3 positive tumors with high affinity and selectivity.